Amgen outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015.

Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming that the Company's strategy will continue to focus on discovery and development of innovative medicines to address serious illnesses, development of branded biosimilars, next-generation bio-manufacturing of high quality biologics, developing improved biologic drug delivery systems, global expansion, and capital allocation and return to shareholders and long-term value opportunities.  Bradway highlighted that while delivering on Amgen's strategy for growth, the Company is transforming to enhance its capabilities to deliver long-term industry-leading innovation and industry-leading financial returns.

"With four potential product launches in 2015 and a strong pipeline of innovative and bio-similar molecules, we are well positioned to deliver breakthrough medicines for patients and drive long-term growth," said Bradway.

Amgen initiated a company-wide re-engineering process in 2013 to ensure clear reallocation of resources to invest in our continuing innovation and the launch of our new pipeline medicines. The Company's transformation includes a significant restructuring, with an approximate 23 percent decrease in facilities footprint and an approximate 20 percent reduction in staff by the end of 2015.  As a result, the Company expects to generate up to $1.5 billion in annual savings and a 15 point adjusted operating margin increase by 2018.

Bradway affirmed Amgen is on track to produce commercial products from its new Singapore next-generation bio-manufacturing facility beginning in 2017.  Next-generation bio-manufacturing will enable dramatically increased bulk production capabilities versus conventional alternatives at one-quarter of the capital costs, one-third of the operating expense, and twice the speed.  The Company estimates these new capabilities will result in an estimated cost reduction of 60 percent or more per gram of protein.

"This is an exciting new era for Amgen.  We are on the cusp of an important new product cycle with our rich pipeline of innovative and biosimilar medicines that address important societal needs," said Bradway. "Our significantly expanded global presence and new bio-manufacturing technologies give us confidence that Amgen is uniquely positioned to capitalize on the latest wave of opportunity for innovative biologic therapies."

Sean E. Harper, M.D., executive vice president of research and development at Amgen discussed Amgen's strategic approach to R&D, progress on operational efficiency, and highlights of the Company's ongoing clinical programmes.

The Company's R&D approach will follow a refined set of guiding principles such as focus on innovative medicines for unmet needs in patients with serious illnesses; emphasis on target validation in humans; modality independence with focus on biologics;focus on return on investment and operational efficiency;harness external innovation; and demonstrate the value of Amgen's medicines.

In addition, Amgen has refocused and differentiated its Discovery Research efforts.  Amgen's Discovery Research efforts are focussed within inflammation and oncology, metabolism and bone, cardiovascular and neuroscience.  The Company has consolidated small, medium and large molecule technologies into one integrated platform; focussed efforts on immuno-oncology; and leveraged its industry-leading position in human population genetics to identify or validate targets in humans wherever possible.

Harper discussed how the Company has deployed deCODE to enhance R&D productivity, citing examples of programmes validated and accelerated or invalidated and terminated.  He also reviewed how the BiTE antibody construct platform is now clinically validated and also attractive for combination approaches.

Harper described the continuous improvement culture that is contributing to the total enterprise annual savings of up to $1.5 billion by 2018; disciplined project prioritisation to maintain focus;partnering strategy to complement core competencies; refocussed discovery research investment;reduced geographic complexity and cost; reduced cycle times for biologics and genetically validated targets; and leaner clinical trial programmes.

"Amgen's world-class modality platform and our ability to associate genetic variation with risk of disease make us uniquely positioned to advance breakthrough medicines to address serious illness," said Harper.  "Our exceptional genetic validation capabilities have strengthened our pipeline, allowing us to 'pick the winners' and focus our investment decisions."

Harper said Amgen's late-stage pipeline is advancing with four programmes currently under regulatory review, phase 3 data expected from three additional programs by the end of this year, phase 3 rilotumumab data expected in 2015, and phase 3 romosozumab data expected in 2016.  Highlights include: Evolocumab: Under regulatory review in the US and Europe for dyslipidemia.  Results from a phase 3 vascular imaging study in 950 patients are expected in 2016.  Our long-term phase 3 outcomes trial has been expanded by 5,000 patients to 27,500, and results are expected no later than 2017 (event-driven).

Ivabradine: under priority review by the US Food and Drug Administration (US FDA) for chronic heart failure.Omecamtiv mecarbil: results from the phase 2b oral formulation study in chronic heart failure patients are expected in 2015.

Romosozumab: results from a phase 3 placebo-controlled study in 6,000 women with postmenopausal osteoporosis are expected in the first half of 2016.  Results from a second event-driven phase 3 study evaluating romosozumab versus alendronate in 4,000 women are expected in 2017. Brodalumab: data from two placebo-controlled studies of brodalumab versus ustekinumab are expected by year-end.  phase 3 psoriatic arthritis data are expected in 2016.AMG 334: Results from a phase 2b episodic migraine study are expected by year-end, followed by results from a phase 2 chronic migraine study in 2016.

Talimogene laherparepvec: under regulatory review in the US and Europe for the treatment of regionally or distantly metastatic melanoma.  data from a phase 2 combination study with ipilimumab are expected in 2016, followed by results from a phase 2 combination study with pembrolizumab in 2017.

Blinatumomab: under priority review by the FDA for relapsed/refractory B-precursor acute lymphocytic leukaemia (ALL); under regulatory review in Europe.  Results from a phase 2 study in adult patients with minimal residual disease positive ALL are expected in 2014 and from a phase 3 study in adult patients with relapsed, refractory ALL in 2016.

Trebananib: Overall survival results from the TRINOVA-1 phase 3 trial in women with recurrent ovarian cancer are expected by year-end.  Progression-free survival data are expected from the TRINOVA-2 first-line ovarian cancer study in 2015.

Rilotumomab: data from an event-driven phase 3 trial evaluating rilotumomab for the treatment of gastric cancer are expected in 2015.AMG 416: Results from a phase 3 trial evaluating AMG 416 versus Sensipar (cinacalcet) for the treatment of secondary hyperparathyroidism are expected in 2015.Harper also discussed AMG 157, a human monoclonal antibody that inhibits the action of Thymic Stromal Lymphopoietin (TSLP), as an example of Amgen's innovative approach in inflammation.

Pablo J. Cagnoni, M.D., president of Amgen's subsidiary, Onyx Pharmaceuticals, Inc., described the substantial growth opportunity for Kyprolis (carfilzomib) in relapsed multiple myeloma based on the unprecedented progression-free survival observed in the ASPIRE study, as well as potential opportunity for weekly dosing administration.  Results from the ENDEAVOR phase 3 head-to-head study versus bortezomib in relapsed patients are expected in 2016, followed by results from the head-to-head CLARION trial in newly diagnosed patients in 2017.  A phase 3 trial evaluating weekly dosing administration is being planned.

Cagnoni also described US launch plans for  blinatumomab in adult relapsed/refractory ALL.

During the meeting, Anthony C. Hooper, executive vice president of Global Commercial Operations at Amgen, described the potential doubling of the product portfolio over the next three years and outlined several growth opportunities, including leveraging strong specialty market experience; driving continued momentum in the current portfolio of growth phase products; successfully launching several new innovative products and biosimilars; and continuing to move into new geographic growth markets. Approximately $2 billion in sales in new and emerging markets in Asia, Turkey and the Middle East, Latin America, and Russia and Eastern Europe are anticipated by 2018.

Hooper provided an update on Amgen's commercial strategy in its five specialty areas.  Highlights include:Inflammation: Enbrel (etanercept) is expected to reach $5 billion in sales ahead of Amgen's biosimilar adililumab launch and realise a step up in profitability starting in November 2016 with expiry of the Pfizer royalty.

Nephrology: Sensipar has the potential to reach approximately $1.5 billion in sales before patent expiry in 2018.

Bone Health: Prolia (denosumab) US share has quadrupled over the past two years and is annualising at $1 billion in sales in 20141.  Romosozumab potentially provides a monthly bone-building alternative for patients with osteoporosis.Oncology: The Company announced that the Neulasta (pegfilgrastim) on-body delivery system is under FDA review.  The commercial opportunity and launch strategy for talimogene laherparepvec was discussed.
Cardiovascular: The commercial opportunity and launch strategy for ivabradine and evolocumab was discussed.

Hooper also discussed how Amgen is transforming its commercial model and contributing to the total enterprise annual savings of up to $1.5 billion by 2018; Focussing on therapeutic areas that leverage the Company's expertise and infrastructure; Enhancing capabilities to derive deeper customer insights and prepare for value and access challenges; Increasing field flexibility to adapt to the changing customer and healthcare provider system landscape; Testing innovative models for engaging patients, providers and payers; and deploying innovative technology to enable customer partnerships.

Scott Foraker, vice president and general manager, Biosimilars, at Amgen, discussed how biosimilars are a good strategic fit for the Company and represent a compelling growth opportunity with the potential to deliver more than $3 billion in annual revenues.  In addition to the biosimilar adilimumab, trastuzumab, bevacizumab, infliximab, rituximab and cetuximab programmes, Amgen has initiated three additional biosimilar programmes.  Foraker noted that Amgen's biosimilar infliximab and rituximab have advanced to the "clinical ready" phase.  Amgen's first biosimilar is expected to launch in 2017, followed by four others through 2019.

Foraker described how Amgen's decades of proven biologics R&D experience, strong biologics manufacturing heritage, track record for high quality and reliable supply, and branded commercial capabilities provide a significant competitive advantage.

David Meline, executive vice president and chief financial officer at Amgen, reviewed the Company's financial strategy and multiple approaches to create shareholder value:

Deliver long-term growth and shareholder returns through new global innovative product launches, biosimilars and international expansion;execute a focussed operating model to increase efficiency, agility, and speed to market while increasing operating margins; and Provide attractive returns to shareholders through share repurchases and dividend growth, while maintaining continuous access to capital markets and investing in the business.

Meline highlighted strong commercial execution, continued pipeline progress, international expansion, transformation efforts and capital allocation strategy.

Meline described how the Company is executing a focussed operating model designed to generate growth, drive innovation, align resources to the highest priorities and support pipeline development, improve key cross-functional processes and create capabilities to drive change and continuous improvement.  The operating model is contributing to adjusted operating margin improvement to 52-54 per cent by 2018.

Meline provided an update on previously announced plans to reduce the Company's global workforce by approximately 2,900 positions by the end of 2015 and reduce its facilities footprint by approximately 23 per cent.  Next steps of the Company's restructuring efforts were announced, including plans to reduce headcount by an additional 600-1,100 positions in 2015.  The additional actions will result in pre-tax accounting charges in the range of $100-$150 million, which are expected to be incurred primarily in 2015.  The total restructuring pre-tax GAAP charges of between approximately $935 million and $1,035 million will be incurred in 2014 and 2015, with $376 million already incurred in the third quarter of 2014.  The focused operating model and combined restructuring actions will result in a total annual savings of up to $1.5 billion and an approximate 15 point adjusted operating margin improvement by 2018.

Meline said that Amgen will continue to execute on its capital allocation strategy focused on supporting the business with a minimum weighted average cost of capital.  Additionally, it is the Company's plan to return, on average, approximately 60 percent of adjusted net income to shareholders through 2018.  The Company plans to increase its dividend 30 per cent in the first quarter of 2015 and to repurchase approximately $2 billion in Amgen shares through year-end 2015; additionally, the Company's share repurchase authorisation has been increased to $4 billion in total.  In addition, Meline affirmed Amgen plans to maintain its investment-grade rating and continuous access to the capital markets.

The Company provided preliminary financial guidance for 2015; Revenues of $20.8-$21.3 billion;Adjusted earnings per share (EPS) of $9.05-$9.40;Adjusted tax rate of 18-19 per cent, excluding the R&D tax credit; and Capital expenditures of approximately $800 million.